All In Biotech

Drug Trial Radar · NCT02741596

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)

Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

May 26, 2016

Primary completion

Oct 31, 2019

Study completion Oct 31, 2019

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Apr 18, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DX-2930Drug

    Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.

  • DX-2930Drug

    Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From start of the study up to follow-up (Day 952)

Locations

43 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama

    Birmingham, Alabama

  • Medical Research of Arizona

    Scottsdale, Arizona

  • University of California San Diego

    San Diego, California

  • AIRE Medical of Los Angeles

    Santa Monica, California

  • Allergy & Asthma Clinical Research

    Walnut Creek, California

  • IMMUNOe Research Centers

    Centennial, Colorado

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado

  • University of South Florida

    Tampa, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Institute Asthma and Allergy

    Chevy Chase, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Midwest Immunology Clinic

    Plymouth, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Hudson-Essex Allergy, LLC

    Belleville, New Jersey

  • Atlantic Research Center, LLC

    Ocean City, New Jersey

  • Winthrop University Hospital

    Mineola, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Clinical Research Center of Charlotte

    Charlotte, North Carolina

  • Duke Asthma, Allergy, and Airway Center

    Durham, North Carolina

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Optimed Research, LTD.

    Columbus, Ohio

  • Toledo Institute of Clinical REsearch

    Toledo, Ohio

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania

  • Austin Regional Clinic

    Austin, Texas

  • AARA Research Center

    Dallas, Texas

  • Intermountain Clinical Research

    Draper, Utah

  • Allergy Associates of Utah

    Murray, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • Premier Clinical Research

    Spokane, Washington

  • Medical College of Wisconsin, Childrens Hospital

    Milwaukee, Wisconsin

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Yang Medicine

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research, Inc.

    Toronto, Ontario, Canada

  • Clinique Spécialisée en Allergie de la Capitale

    Québec, Quebec, Canada

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Hautklinik der Universitätsmedizin Mainz

    Mainz, Germany

  • HZRM Hamophilie Zentrum Rhein Main GmbH

    Mörfelden-Walldorf, Germany

  • University of Milan Luigi Sacco Hospital

    Milan, Italy

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.